Looking to Partner with the World CNS Series?
Following a year of significant pharma acquisitions, approvals of transformative drugs the first of their kind, and a surge of financial backing to bolster innovation in new targets and preclinical pipelines, 2026 is set to continue this momentum, with more companies prioritising neuroscience drug development than ever before.
If you have relevant capabilities in this space and would like to align your brand with the CNS community, contact us to promote your capabilities through a bespoke commercial package.
Having trouble downloading the brochure? Let us know and we’ll email it to you instead.
Download Your Copy of the Sponsorship Prospectus
Explore the Agenda
Discover the latest case studies and practical strategies shaping the future of CNS biomarker development from Lundbeck, Roche, UCB & more.
Partner With Us
Position your brand alongside Europe's leading biomarker innovators and connect with decision-makers actively seeking new technologies and partners.
Join Biopharma Experts
Exchange ideas with biomarker, translational medicine and clinical development leaders tackling the biggest challenges in neurodegenerative drug development.